PTC Therapeutics | PTCT - Ebitda

Stock Price
71.47
Daily Change
-1.25 -1.72%
Monthly
-0.32%
Yearly
55.34%
Q2 Forecast
70.03

PTC Therapeutics reported $-70.99M in EBITDA for its fiscal quarter ending in December of 2025.





Ebitda Change Date
Acadia Pharmaceuticals USD 20.31M 15.44M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amgen USD 5.14B 775M Dec/2025
BioCryst Pharmaceuticals USD 51.7M 30.14M Sep/2025
Biogen USD 649.7M 76.5M Mar/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Daiichi Sankyo JPY 101.6B 22.81B Mar/2025
Esperion Therapeutics USD -9.93M 24.99M Sep/2025
Gilead Sciences USD 3.02B 1.01B Dec/2025
Incyte USD 367.97M 46.53M Mar/2026
Ionis Pharmaceuticals USD -200.02M 42.89M Dec/2025
Ironwood Pharmaceuticals USD 81.81M 31.71M Sep/2025
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Novartis USD 5.3B 530M Mar/2026
Pfizer USD 5.99B 5.23B Mar/2026
PTC Therapeutics USD -70.99M 91.62M Dec/2025
Puma Biotechnology USD 729K 11.36M Jun/2024
Roche Holding CHF 12.68B 2.36B Jun/2024
Sarepta Therapeutics USD -252.2M 84.16M Dec/2025
TG Therapeutics USD 51.69M 19M Dec/2025
Ultragenyx Pharmaceutical USD -99.43M 57.35M Dec/2025
Vertex Pharmaceuticals USD 1.19B 195.3M Mar/2026
Xencor USD -51.05M 55.28M Dec/2025